Related to RainDance Forges Separate Pacts with Ambry and Roche to Advance ADME Analysis

• Roche, Swiss Academia Establish Translational Research Collaboration
  
• Roche, Technoclone Partner to Develop Coagulation Assays
  
• EC Clears Roche, Plexxikon’s Zelboraf for BRAF V600-Mutated Melanoma
  
• Academia-Industry Project Secures $38.7M for Autism Spectrum Disorders
  
• Roche Plans 2012 Filing for Breast Cancer Antibody-Drug Conjugate
  
• 454, SoftGenetics Enter Co-Promotion Deal in Next-Gen Sequencing Informatics
  
• ThromboGenics, BioInvent Regain TB-403 from Roche and Ditch Anticoagulant TB-402
  
• Roche Goes to Seaside for Collaboration on Fragile X Syndrome, Autism Therapies
  
• Galapagos and Roche Call It Quits
  
• Roche, Ascletis to Develop HCV Drug in China
  
• Roche Gains Access to Cerep’s Pharmacology and ADME Database
  
• Eurofins to Provide Roche GS Junior for Smaller-Scale Projects
  
• Roche to Assess Cerep's BioPrint Database and Pharmaco-Informatics Tools
  
• Roche and Precision System Science Deal to Advance NGS
  
• Ambry Confirmed as First U.S. CSP for NimbleGen Sequence-Capture Solution
  
• IDT to Provide Custom Primers for Sequencing on 454’s GS FLX and GS Junior Platforms
  
• Fluidigm and 454 to Co-Promote Access Array and Sequencing Systems Worldwide
  
• Ambry Purchases RainDance’s ThunderStorm System for Targeted Sequencing
  
• Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing
  
• Ambry to Offer Sequence-Enrichment Capabilities with RainDance’s RDT1000 Platform